Fresenius SE KGaA (XSWX:FRE) Short-term investments


XSWX:FRE Fresenius SE & Co KGaA XSWX:FRE
71 GF Score
Price CHF36.15
GF Value CHF32.22
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Fresenius SE KGaA Short-term investments?

Short-term investments only applies to insurance companies.

XSWX:FRE
71GF Score
Fresenius SE & Co KGaA XSWX:FRE
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued. The current stock price of CHF36.15 is trading 12.2% above its estimated GF Value™ of CHF32.22. GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.

Key valuation signals for XSWX:FRE:

  • Short-term investments:
  • GF Value™: CHF32.22 vs. price of CHF36.15 (12.2% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fresenius SE KGaA Business Description

Address Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score

Get the complete analysis for XSWX:FRE

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF36.15
Price
CHF32.22
GF Value